In a Phase 2 study evaluating eprenetapopt in combination with azacitidine in TP53 mutant patients with MDS and AML (NCT03072043), the overall response rate was 71%, with 44% achieving CR [105]. Here, TP53 is linked to myelodysplastic syndrome.